knowledge -WSS

knowledge

author：leisure time 2025-09-02 22:01:27 - browse：8815

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： The drug industry sees a key ally in the Senate prevail

entertainment

WSS

Methadone treatment changes are coming. Do they go far enough?

Future doctors should be trained to promote social change

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

ProMED, early warning system on disease outbreaks, in peril

Microsoft strikes partnership with Duke Health to advance health AI

The drug industry sees a key ally in the Senate prevail

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Leading voice in opioid treatment defends methadone clinic system

Apple is now the first public company to be valued at $3 trillion

Microsoft strikes partnership with Duke Health to advance health AI

Sports medicine is finally prioritizing gender equality

Nurses recount patients attacks

Anesthesiologist group: stop taking Ozempic before surgery

Creating egg and sperm cells from stem cells raises ethical issues

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Colonoscopy prep: Liquid

entertainment

UnitedHealth increases loan offers after Change Healthcare outage

Positive childhood experiences can help future health

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

White House drug shortage group privately met with industry

Plastic surgeons increase patient psychiatric screenings

Future doctors should be trained to promote social change

explore

entertainment

focus

hotspot